SRD5A2
SRD5A2 (steroid 5 alpha-reductase 2) is a microsomal enzyme that reduces the delta 4,5 bond of 3-oxo steroids, converting testosterone into 5-alpha-dihydrotestosterone (DHT). It is also known as 3-oxo-5-alpha-steroid 4-dehydrogenase 2. Browse Assay Genie's current range of SRD5A2 research reagents below, or read on for the biology behind the target.
SRD5A2 catalyses the irreversible, stereospecific reduction of the delta 4,5 bond (the double bond between carbons 4 and 5) of various 3-oxo steroids, producing their 5-alpha dihydro-3-oxo forms. Its best-characterised reaction is the conversion of testosterone into 5-alpha-dihydrotestosterone (DHT), the most active androgen in the prostate and the preferred ligand for androgen receptor (AR) transactivation. This step is key to male sexual differentiation during development. The enzyme can also act on other steroids, including progesterone, producing metabolites with diverse roles, and so plays a central role in sexual differentiation and androgen physiology.
The SRD5A2 gene encodes a microsomal protein, found in the microsome and endoplasmic reticulum membrane, and expressed at high levels in androgen-sensitive tissues such as the prostate. The encoded protein is active at acidic pH and is sensitive to the 4-azasteroid inhibitor finasteride. It belongs to the steroid 5-alpha reductase family, and mouse and rat orthologs are both designated Srd5a2. Another family member, SRD5A1, is a useful comparator in studies of 5-alpha reduction.
Deficiencies in the SRD5A2 gene can result in male pseudohermaphroditism, specifically pseudovaginal perineoscrotal hypospadias (PPSH). The HGNC previous name, steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2), reflects the enzyme's activity. Researchers studying SRD5A2 protein levels, activity or inhibition often work in androgen-responsive tissue models.
SRD5A2 converts testosterone to DHT, the preferred ligand for androgen receptor transactivation, making it central to studies of androgen signalling.
The enzyme is expressed at high levels in androgen-sensitive tissues such as the prostate, where DHT is the most active androgen.
DHT production by SRD5A2 is a key step in male sexual differentiation during development, and deficiency can cause pseudovaginal perineoscrotal hypospadias.
SRD5A2 is sensitive to the 4-azasteroid inhibitor finasteride, making it a reference target for studying 5-alpha-reductase inhibition.
SRD5A2 catalyses the irreversible reduction of the delta 4,5 bond of 3-oxo steroids. It converts testosterone into 5-alpha-dihydrotestosterone (DHT), the preferred ligand for androgen receptor transactivation, and can also act on steroids such as progesterone. It therefore has a central role in sexual differentiation and androgen physiology.
The protein is named 3-oxo-5-alpha-steroid 4-dehydrogenase 2 in UniProt and steroid 5 alpha-reductase 2 by HGNC. Its previous HGNC name was steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2). The enzyme is classified as EC 1.3.1.22.
Deficiencies in the SRD5A2 gene can result in male pseudohermaphroditism, specifically pseudovaginal perineoscrotal hypospadias (PPSH). Mouse and rat each have an ortholog named Srd5a2. Check the datasheet of any product for its validated reactivity.
Other steroid 5-alpha reductase family members and related targets in androgen metabolism with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P31213; product specifications from Assay Genie datasheets.